

# Creativity. Capability. Capital.

**AusBiotech2011**  
AUSTRALIA'S BIOTECHNOLOGY CONFERENCE



16 to 19 October 2011  
Adelaide Convention Centre, South Australia  
[www.ausbiotech2011.com.au](http://www.ausbiotech2011.com.au)



## AUSBIOTECH 2011 CONFERENCE SPEAKERS' PROFILE

**Dr Cathal O'Reilly**  
**Managing Director**  
**Centerview Partners**  
**London, United Kingdom**



Dr. Cathal O'Reilly is a Managing Director at Centerview Partners, based in the London office. Centerview Partners is a US-headquartered investment banking partnership focused on several major global industry sectors, including consumer products, healthcare, financial institutions, technology and media. Selected advisory roles of note for the firm include the spin offs of Philip Morris (\$113bn) and Kraft (\$62bn) by Altria, the acquisition of Anheuser-Busch (\$52bn) by InBev, the acquisition of Cadbury (\$22bn) by Kraft, the acquisition of The Pepsi Bottling Group and PepsiAmericas by Pepsi (\$21bn), the acquisition of UST (\$12bn) by Altria, the spin off of Motorola Mobility (\$10bn) by Motorola, the acquisition of ING Direct (\$9bn) by Capital One Financial, the acquisition of Wimm-Bill-Dann Foods (\$5bn) by Pepsi and the acquisition of Dow Jones (\$5bn) by News Corporation.

Since the foundation of the healthcare franchise within Centerview in 2009, the team has advised on \$18bn of M&A situations, including the acquisition of Nationwide Health Properties (\$7bn) by Ventas, the sale of OSI (\$4bn) to Astellas, the sale of NBTY (\$4bn) to Carlyle, the acquisition of Altria Senior Living (\$3bn) by Ventas, the acquisition of a majority stake in Stallergenes (\$0.8bn) by Ares Life Sciences and the sale of Facet Biotech (\$0.7bn) to Abbott.

During 12 years in investment banking, Dr. O'Reilly has advised several major healthcare companies across a number of M&A and financing situations. Over the period, he has been mainly focused on large and specialty pharmaceuticals, biopharmaceuticals and wholesale/distribution services. Selected strategic advisory transactions on which he has worked include the LBO of Alliance Boots (\$25bn) by KKR and Stefano Pessina, AstraZeneca's acquisition of MedImmune (\$15bn), the merger of Alliance UniChem and Boots (\$12bn), the proposed acquisition of Talecris (\$3bn) by CSL (not completed), the acquisition of Aventis Behring (\$1bn) by CSL, the acquisition of a majority stake in Stallergenes (\$0.8bn) by Ares Life Sciences, the

sale of JRH Biosciences (\$0.4bn) to Sigma Aldrich and the acquisition of Arius Research (\$0.2bn) by Roche. He has also worked on the \$16.5bn inaugural US\$ bond issuance by Roche which was part of the financing of the Genentech transaction, the \$2.5bn IPO of Alcon, the \$1.5bn equity placement in Sanofi-Synthélabo by TotalFinaElf, the \$0.6bn 24 year benchmark sterling bond for AstraZeneca and the \$0.4bn equity offering by Galen (Warner Chilcott).

Dr. O'Reilly was previously a Director of Healthcare Investment Banking at Merrill Lynch, based in the London office. He holds B.Sc. (Pharm) and PhD degrees from Trinity College Dublin. He is also chartered financial analyst (CFA charterholder).